Skip to Main Content
Table 4.

Changes toward intended and reported adherence to monthly SSEs and changes in the absolute and relative intended frequency of SSEs immediately after genetic test reporting and at the 1-mo follow-up in each group and as a function of baseline screening status

Carriers
Noncarriers
CDKN2A/p16+ no melanoma history
CDKN2A/p16+ melanoma history
CDKN2A/p16 no melanoma history
BaselinePostcounseling1 moBaselinePostcounseling1 moBaselinePostcounseling1 mo
Change toward adherence to monthly SSEs*  +0.78 +1.70  −0.04 −0.45§  +0.20 +0.15 
Intended and reported number of SSEs per month          
    Underscreeners 0.22 1.11 2.25 0.27 0.79 0.50 0.43 0.53 0.75 
    Overscreeners,** 15.12 2.25 6.25 4.10 2.74 7.20 11.87 2.47§ 2.00 
    On-target screeners†† — — — 1.00 1.50 1.63 1.00 1.00 2.00 
Intended SSEs in future relative to current practice‡‡          
    Underscreeners  4.78   3.75§   3.82  
    Overscreeners  3.60   3.43   3.20  
    On-target screeners  —   3.33   3.25  
    Total sample  4.36   3.47   3.63  
          
 Total sample
 
  

 
Baseline
 
Postcounseling
 
1 mo
 
Change toward adherence to monthly SSEs  +0.26§ +0.38 
Intended and reported number of SSEs per month    
    Underscreeners 0.34 0.74§ 1.18 
    Overscreeners 9.29 2.53 5.58 
    On-target screeners 1.00 1.30 1.79 
Intended SSEs in future relative to current practice    
    Underscreeners  4.10  
    Overscreeners  3.42  
    On-target screeners  3.30§  
    Total sample  3.76  
Carriers
Noncarriers
CDKN2A/p16+ no melanoma history
CDKN2A/p16+ melanoma history
CDKN2A/p16 no melanoma history
BaselinePostcounseling1 moBaselinePostcounseling1 moBaselinePostcounseling1 mo
Change toward adherence to monthly SSEs*  +0.78 +1.70  −0.04 −0.45§  +0.20 +0.15 
Intended and reported number of SSEs per month          
    Underscreeners 0.22 1.11 2.25 0.27 0.79 0.50 0.43 0.53 0.75 
    Overscreeners,** 15.12 2.25 6.25 4.10 2.74 7.20 11.87 2.47§ 2.00 
    On-target screeners†† — — — 1.00 1.50 1.63 1.00 1.00 2.00 
Intended SSEs in future relative to current practice‡‡          
    Underscreeners  4.78   3.75§   3.82  
    Overscreeners  3.60   3.43   3.20  
    On-target screeners  —   3.33   3.25  
    Total sample  4.36   3.47   3.63  
          
 Total sample
 
  

 
Baseline
 
Postcounseling
 
1 mo
 
Change toward adherence to monthly SSEs  +0.26§ +0.38 
Intended and reported number of SSEs per month    
    Underscreeners 0.34 0.74§ 1.18 
    Overscreeners 9.29 2.53 5.58 
    On-target screeners 1.00 1.30 1.79 
Intended SSEs in future relative to current practice    
    Underscreeners  4.10  
    Overscreeners  3.42  
    On-target screeners  3.30§  
    Total sample  3.76  

NOTE: Values in boldface indicate significant changes from baseline.

*

Positive values indicate change in either direction toward adherence to the recommendation of 1 SSE/mo; negative values indicate a change in either direction away from the recommendation of 1 SSE/mo. Values in boldface are significantly different from 0 (no change).

P < 0.01.

P < 0.001.

§

P < 0.05.

Of the 30 underscreeners at baseline, 1-mo follow-up data were available for 6 of 9 participants in the CDKN2A/p16+ no melanoma history group, 2 of 4 participants in the CDKN2A/p16+ melanoma history group, and 13 of 17 participants in the CDKN2A/p16 group.

Of the 18 overscreeners at baseline, 1-mo follow-up data were available for 4 of 5 participants in the CDKN2A/p16+ no melanoma history group, 5 of 8 participants in the CDKN2A/p16+ melanoma history group, and 3 of 5 in the CDKN2A/p16 group.

**

These results are likely to underestimate overscreening intentions immediately following test reporting. It is important to note that the highest score participants could receive at the postcounseling assessment was 4 SSEs/mo (intentions to practice SSEs once a week or more frequently). However, the results reported for significant decreases from baseline in intentions to practice SSEs remained the same when an analogous baseline SSE measure based on verbal descriptors was used to evaluate changes from baseline in postcounseling SSE intentions.

††

Of the 10 on-target screeners at baseline, 1-mo follow-up data were available for 4 of 6 participants in the CDKN2A/p16+ melanoma history group and 3 of 4 participants in the CDKN2A/p16 group.

‡‡

1, much less than I have been doing; 5, much more than I have been doing. Boldfaced values indicate that the group mean was significantly >3.0 (“about the same as I have been doing”) and thus represents a significant intention to increase SSEs relative to current practice.

Close Modal

or Create an Account

Close Modal
Close Modal